Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

被引：14

作者：

Cortes-Selva, Diana ^{[1
]}

Perova, Tatiana ^{[1
]}

Skerget, Sheri ^{[1
]}

Vishwamitra, Deeksha ^{[1
]}

Stein, Sarah ^{[1
]}

Boominathan, Rengasamy ^{[1
]}

Lau, Onsay ^{[1
]}

Calara-Nielsen, Karl ^{[1
]}

Davis, Cuc ^{[1
]}

Patel, Jaymala ^{[1
]}

Banerjee, Arnob ^{[1
]}

Stephenson, Tara ^{[1
]}

Uhlar, Clarissa ^{[1
]}

Kobos, Rachel ^{[2
]}

Goldberg, Jenna ^{[2
]}

Pei, Lixia ^{[2
]}

Trancucci, Danielle ^{[2
]}

Girgis, Suzette ^{[1
]}

Lin, Shun Xin Wang ^{[1
]}

Wu, Liviawati S. ^{[3
]}

Moreau, Philippe ^{[4
]}

Usmani, Saad Z. ^{[5
]}

Bahlis, Nizar J. ^{[6
]}

van de Donk, Niels W. C. J. ^{[7
]}

Verona, Raluca I. ^{[1
]}

机构：

[1] Janssen Res & Dev, Spring House, PA USA

[2] Janssen Res & Dev, Raritan, NJ USA

[3] Janssen Res & Dev, South San Francisco, CA USA

[4] Univ Hosp Hotel Dieu, Nantes, France

[5] Mem Sloan Kettering Canc Ctr, New York, NY USA

[6] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[7] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands

来源：

BLOOD | 2024年 / 144卷 / 06期

关键词：

T-CELLS; BISPECIFIC ANTIBODY; PHASE-III; NAIVE; DEXAMETHASONE; DARATUMUMAB; EFFECTOR; OUTCOMES;

D O I：

10.1182/blood.2023022823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) x CD3 bispecific fi c antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (R/RMM). As a T-cell redirection therapy, clinical outcomes with teclistamab may be influenced fl uenced by patient immune fi tness and tumor antigen expression. We correlated tumor characteristics and baseline immune profiles fi les with clinical response and disease burden in patients with R/RMM from the pivotal phase 1/2 MajesTEC-1 study, focusing on patients treated with 1.5 mg/kg of teclistamab (N =165). Peripheral blood samples were collected at screening, and bone marrow samples were collected at screening and cycle 3. Better clinical outcomes to teclistamab correlated with higher baseline total T-cell counts in the periphery. In addition, responders (partial response or better) had a lower proportion of immunosuppressive regulatory T cells (Tregs), T cells expressing coinhibitory receptors (CD38, PD-1, and PD-1/TIM-3), and soluble BCMA and a T-cell profile fi le suggestive of a more cytolytic potential, compared with nonresponders. Neither frequency of baseline bone marrow BCMA expression nor BCMA-receptor density was associated with clinical response to teclistamab. Improved progression-free survival was observed in patients with a lower frequency of T cells expressing exhaustion markers and immunosuppressive Tregs. Overall, response to teclistamab was associated with baseline immune fi tness; nonresponders had immune profiles fi les suggestive of immune suppression and T-cell dysfunction. These fi ndings illustrate the importance of the contribution of the immune landscape to T-cell redirection therapy response. This trial was registered at www.ClinicalTrials.gov as #NCT03145181/ NCT04557098.

引用

页码：615 / 628

页数：14